Michele Stansfield is Co-Founder and CEO of Cauldron, a global biomanufacturer unlocking price parity for mainstream bio-manufactured goods. Stansfield was the driving force behind Cauldron’s management acquisition of Agritechnology, a bioscience company based in Australia that developed the proprietary hyper-fermentation technology at Cauldron’s core. Having served as Agritechnology’s General Manager for over a decade using microbes to produce vaccines, food, feed and fuel, she has industry-leading expertise in the scale-up and commercialization of continuous fermentation biomanufacturing. With a background in biomedical science and cellular and molecular biology, Stansfield began her career at Pfizer, focused on a novel pharmaceutical therapy used in the pork industry. She holds a BSc with honours in biomedical science, cellular and molecular biology from the University of Western Sydney.